论文部分内容阅读
目的探讨放射性~(125)I粒子植入治疗中重度癌性疼痛的临床疗效及安全性。方法选取80例中重度癌性疼痛患者,采取数字表法随机分为观察组(n=40)和对照组(n=40)。对照组给予常规药物治疗,观察组给予放射性~(125)I粒子植入治疗。比较两组患者疼痛数字评分量表(NRS)、疼痛缓解率、日平均疼痛时间及不良反应。结果治疗后1 d,两组患者的NRS评分比较差异无统计学意义(P>0.05);治疗后3 d、7 d、14 d、28 d,观察组患者NRS评分明显低于对照组,组间比较差异均具有统计学意义(P<0.05);观察组的疼痛缓解率为90.0%,明显高于对照组的60.0%,组间比较差异有统计学意义(P<0.05);治疗后28 d,观察组日平均疼痛时间为(1.2±0.5)h,明显短于对照组的(3.0±0.4)h,不良反应发生率为2.5%,明显低于对照组的22.5%,组间比较差异均具有统计学意义(P<0.05)。结论放射性~(125)I粒子植入治疗中重度癌性疼痛的效果优于常规药物治疗,且不良反应少。
Objective To investigate the clinical efficacy and safety of radioactive 125 I seed implantation in the treatment of moderate-severe cancerous pain. Methods Eighty patients with moderate to severe cancerous pain were selected and randomly divided into observation group (n = 40) and control group (n = 40) by digital meter. Control group was given conventional drug treatment, the observation group was given radioactive 125I I particle implantation. The pain score scale (NRS), pain relief rate, mean daily pain time, and adverse reactions were compared between the two groups. Results There was no significant difference in NRS scores between the two groups on the 1st day after treatment (P> 0.05). The NRS scores of the observation group were significantly lower than those of the control group on the 3rd, 7th, 14th, 28th day after treatment (P <0.05). The pain relief rate in the observation group was 90.0%, which was significantly higher than that in the control group (60.0%), with significant difference between the two groups (P <0.05). After treatment, 28 d, the average pain time in the observation group was (1.2 ± 0.5) h, significantly shorter than that in the control group (3.0 ± 0.4) h, the incidence of adverse reactions was 2.5%, significantly lower than the control group, 22.5% All were statistically significant (P <0.05). Conclusion Radioactive 125 I seed implantation is superior to conventional medical therapy in the treatment of moderate-severe cancerous pain with less adverse reactions.